Alzheimer's Disease Therapeutics Market to 2019 - New Report

GBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation". The Alzheimer's Disease (AD) market is characterized by a lack of products with strong disease-modifying properties and a number of high-profile product failures in late stages of development over recent years. In addition, recent or impending patent expiries for all of the four currently marketed products and a late-stage pipeline with limited-to-moderate prospects are expected to impede growth over the next few years. In the medium-term future, the market is expected to be characterized by substantial generic competition and overall decline. However, the current development pipeline shows signs of meaningful innovation, although the vast majority of these products are currently in the early stages of development. Despite one of the highest drug attrition rates across the industry, a number of innovative and potentially disease-modifying therapeutics are likely to enter the market and translate recent insights into the etiology of AD combined with an earlier therapeutic intervention into better products, which will begin to transform the AD market towards the end of the decade.

Full Report Details at
- http://www.fastmr.com/prod/739007_alzheimers_disease_therapeutics_market_to_2019.aspx?afid=301

Scope

* A brief introduction to AD etiology, pathogenesis, diagnosis, and treatment regimes
* Profiling of the marketed products in the AD market, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses
* Comprehensive review of the pipeline for AD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type, and molecular target.
* Additional in-depth analysis of pipeline drug clinical trials, analyzed by phase, molecule type, trial size, trial duration and program failure rate, for each molecule type and mechanism of action
* Multi-scenario forecast data for the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Japan, Germany, the UK, France, Italy and Spain
* Discussion of the drivers of and barriers to market growth
* Analysis of the licensing and co-development deals landscape

Reasons to Get this Report

* Understand the different levels of AD therapies, from early-stage or mild AD to severe AD
* Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Alzheimer's Disease - Pipeline Review, H2 2013
- Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2013
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2012
- Alzheimer's Disease - Pipeline Review, H1 2013